Extracorporeal Renal Replacement

Principles of Regenerative Medicine

Volumn , Issue , 2011, Pages 943-953

  Johnston, Kimberly A ^a   Humes, H David ^b  

^a Biotherapies Inc   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862120907     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381422-7.10051-3     Document Type: Chapter

References (43)

1. Bologa R.M., Levine D.M., Parker T.S., Cheigh J.S., Serur D., Stenzel K.H., et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am. J. Kidney Dis. 1998, 32:107-114.
2. Bone R.C. The pathogenesis of sepsis. Ann. Intern. Med. 1991, 115:457-469.
3. Buffington D.A., Hageman G., Wang M., Ding F., Song J., Jung J., et al. (Abstract). Design of a compact cryopreservable bioartificial renal cell system. J. Am. Soc. Nephrol. 2009, 20:27A.
4. Dinarello C.A. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and the treatment of the septic shock syndrome. J. Infect. Dis. 1991, 163:1177-1184.
5. Ding F., Song J.H., Lou L., Rojas A., Reoma J.L., Cook K.E., et al. A novel selective cytopheretic inhibitory device (SCD) inhibits circulating leukocyte activation and ameliorates multiorgan dysfunction in a porcine model of septic shock. (Abstract.). J. Am. Soc. Nephrol. 2008, 19:458A.
6. Eknoyan G., Beck G.J., Cheung A.K., Daugirdas J.T., Greene T., Kusek J.W., et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N. Engl. J. Med. 2002, 347:2010-2019. for the Hemodialysis (HEMO) Study Group.
7. Emoto M., Miyamoto M., Yoshizawa I., Emoto Y., Schaible U.E., Kita E., et al. Critical role of NK cells rather than Vα14+NKT cells in lipopolysaccharide-induced lethal shock in mice. J. Immunol. 2002, 169:1426-1432.
8. Fissell W.H., Dyke D.B., Buffington D.A., Weitzel W.F., Westover A.J., MacKay S.M., et al. Bioartificial kidney alters cytokine response and hemodynamics in endotoxin-challenged uremic animals. Blood Purif. 2002, 20:55-60.
9. Fissell W.H., Humes H.D., Roy S., Fleischman A. Initial characterization of a nanoengineered ultrafiltration membrane. J. Am. Soc. Nephrol. 2002, 13:602A.
10. Fissell W.H., Lou L., Abrishami S., Buffington D.A., Humes H.D. Bioartificial kidney ameliorates gram-negative bacteria-induced septic shock in uremic animals. J. Am. Soc. Nephrol. 2003, 14:454-461.
11. Fissell W.H., Manley S., Westover A., Humes H.D., Fleischman A.J., Roy S. Differentiated growth of human renal tubule cells on thin-film and nanostructured materials. ASAIO J. 2006, 52:221-227.
12. Gura V., Beizai M., Ezon C., Polaschegg H.D. Continuous renal replacement therapy for end-stage renal disease. The wearable artificial kidney (WAK). Contrib. Nephrol. 2005, 149:325.
13. Humes H.D., Cieslinski D.A. Interaction between growth factors and retinoic acid in the induction of kidney tubulogenesis in tissue culture. Exp. Cell Res. 1992, 201:8-15.
14. Humes H.D., Krauss J.C., Cieslinski D.A., Funke A.J. Tubulogenesis from isolated single cells of adult mammalian kidney: clonal analysis with a recombinant retrovirus. Am. J. Physiol. 1996, 271(1 Pt 2):F42-F49.
15. Humes H.D., Buffington D.A., MacKay S.M., Funke A.J., Weitzel W.F. Replacement of renal function in uremic animals with a tissue-engineered kidney. Nat. Biotechnol. 1999, 17:451-455.
16. Humes H.D., MacKay S.M., Funke A.J., Buffington D.A. Tissue engineering of a bioartificial renal tubule assist device: in vitro transport and metabolic characteristics. Kidney Int. 1999, 55:2502-2514.
17. Humes H.D., Fissell W.H., Weitzel W.F., Buffington D.A., Westover A.J., MacKay S.M., et al. Metabolic replacement of kidney function in uremic animals with a bioartificial kidney containing human cells. Am. J. Kidney Dis. 2002, 39:1078-1087.
18. Humes H.D., Buffington D.A., Lou L., Abrishami S., Wang M., Xia J., et al. Cell therapy with a tissue-engineered reduces the multiple-organ consequences of septic shock. Crit. Care Med. 2003, 31:2421-2428.
19. Humes H.D., Weitzel W.F., Bartlett R.H., Swaniker F.C., Paganini E.P., Luderer J.R., et al. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int. 2004, 66:1578-1588.
20. Humes H.D., Buffington D.A., Lou L., Wang M., Abrishami S. Renal cell therapy ameliorates pulmonary abnormalities in a large animal model of septic shock and acute renal injury. J. Am. Soc. Nephrol. 2007, 18:A382.
21. Humes H.D., Dillon J., Tolwani A., Cremisi H., Wali R., Murray P., et al. A novel selective cytopheretic inhibitory device (SCD) improves mortality in ICU patients with acute kidney injury (AKI) and multiorgan failure (MOF) in a phase II clinical study. J. Am. Soc. Nephrol. 2008, 19:458A.
22. Joyce D.A., Gibbons D.P., Green P., Steer J.H., Feldmann M., Brennan F.M. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur. J. Immunol. 1994, 24:2699-2705.
23. Kielar M., Jeyarajah D.R., Lu C.Y. The regulation of ischemic acute renal failure by extrarenal organs. Curr. Opin. Nephrol. Hypertens. 2002, 11:451-457.
24. Kimmel P.L., Phillips T.M., Simmens S.J., Peterson R.A., Weihs K.L., Alleyne S., et al. Immunologic function and survival in hemodialysis patients. Kidney Int. 1998, 54:236-244.
25. le Tissier P., Stoye J.P., Takeuchi Y., Patience C., Weiss R.A. Two sets of human-tropic pig retrovirus. Nature 1997, 389:681-682.
26. Magistrelli J.M. Investigating Fluid Flow Through Silicon Nanoporous Membranes. Master's thesis 2004, Case Western Reserve University, Cleveland.
27. Marchant A., Bruyns C., Vandenabeele P., Ducarne M., Gerard C., Delvaux A., et al. Interleukin-10 controls interferonγ and tumor necrosis factor production during experimental endotoxemia. Eur. J. Immunol. 1994, 24:1167-1171.
28. Maroszynska I., Fiedor P. Leukocytes and endothelium interaction as rate limiting step in the inflammatory response and a key factor in the ischemia-reperfusion injury. Ann. Transplant. 2000, 5:5-11.
29. Matsumoto T., Tateda K., Miyazaki S., Furuya N., Ohno A., Ishii Y., et al. Effect of interleukin-10 on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob. Agents Chemother. 1998, 42:2853-2857.
30. Natanson C. Studies using a canine model to investigate the cardiovascular abnormality of and potential therapies for septic shock. Clin. Res. 1990, 38:206-214.
31. Natanson C., Danner R.L., Elin R.J., Hosseini J.M., Peart K.W., Banks S.M., et al. Role of endotoxemia in cardiovascular dysfunction and mortality: Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J. Clin. Invest. 1989, 83:243-251.
32. Neilson E.G., Hull A.R., Wish J., Neylan J.F., Sherman D., Suki W.N. The Ad Hoc Committee Report on estimating the future workforce and training requirements for nephrology. J. Am. Soc. Nephrol. 1997, 8(5 Suppl. 9):S1-S4.
33. Okusa M.D. The inflammatory cascade in acute ischemic renal failure. Nephron 2002, 90:133-138.
34. Paradis K., Langford G., Long Z., Heneine W., Sandstrom P., Switzer W.M., et al. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. Science 1999, 285:1236-1241. The XEN 111 Study Group, Otto, E.
35. Pinsky M.R., Vincent J.L., Deviere J., Alegre M., Kahn R.J., Dupont E. Serum cytokine levels in human septic shock. Chest 1993, 103:565-576.
36. Redmond H.P., Chavin K.D., Bromberg J.S., Daly J.M. Inhibition of macrophase-activating cytokines is beneficial in the acute septic response. Ann. Surg. 1991, 214:502-508.
37. Ronco C., Fecondini L. The Vicenza wearable artificial kidney for peritoneal dialysis (ViWAK PD). Blood Purif. 2007, 25:383-388.
38. Simmons E.M., Himmelfarb J., Sezer M.T., Chertow G.M., Mehta R.L., Paganini E.P., et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 2004, 65:1357-1365. for the PICARD study group.
39. Tumlin J., Wali R., Williams W., Murray P., Tolwani A.J., Vinnikova A.K., et al. Efficacy and safety of renal tubule cell therapy for acute renal failure. J. Am. Soc. Nephrol. 2008, 19(5):1034-1040.
40. US Renal Data System USRDS 2002 Annual Data Report, Atlas of End-Stage Renal Disease in the United States 2004, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
41. Walley K., Lukacs N., Standiford T., Streiter R., Kunkel S. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect. Immunol. 1996, 64:4733-4738.
42. Ward R.A., Leypoldt J.K., Clark W.R., Ronco C., Mishkin G.J., Paganini E.P. What clinically important advances in understanding and improving dialyzer function have occurred recently?. Semin. Dial. 2001, 14:160-174.
43. Zimmermann J., Herrlinger S., Pruy A., Metzger T., Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999, 55:648-658.